A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
220actual
Sites
164
Countries
Argentina, Brazil, Chile +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-15 | actual | When the study began enrolling |
| Primary completion | 2025-07-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-29 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Nonalcoholic Steatohepatitis
Interventions
- Drug: AZD2693
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants achieving NASH resolution without worsening of fibrosis based on histology after 52 weeks treatment
measured after 52 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed